Fresenius Medical Care (NYSE:FMS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report released on Saturday morning. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial cut their price objective on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating on the stock in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Hold and an average price target of $22.00.

Fresenius Medical Care Stock Down 0.7 %

NYSE:FMS opened at $20.94 on Friday. The firm has a market capitalization of $12.29 billion, a P/E ratio of 23.53, a PEG ratio of 1.09 and a beta of 0.90. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $23.29. The company’s fifty day moving average price is $19.48 and its 200-day moving average price is $19.90. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. As a group, equities research analysts anticipate that Fresenius Medical Care will post 1.51 EPS for the current year.

Institutional Trading of Fresenius Medical Care

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kimelman & Baird LLC acquired a new stake in Fresenius Medical Care during the second quarter valued at $186,000. Creative Planning grew its position in Fresenius Medical Care by 18.9% during the second quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after buying an additional 6,373 shares during the period. AQR Capital Management LLC acquired a new stake in Fresenius Medical Care during the second quarter valued at $197,000. Marshall Wace LLP grew its position in Fresenius Medical Care by 8.5% during the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after buying an additional 1,207 shares during the period. Finally, XTX Topco Ltd grew its position in shares of Fresenius Medical Care by 82.1% in the second quarter. XTX Topco Ltd now owns 23,282 shares of the company’s stock valued at $444,000 after purchasing an additional 10,497 shares during the period. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.